The Poche Centre to host 3D total-body imaging system as part of world-first initiative to save lives from melanoma
29 November 2018
Melanoma Institute Australia (MIA) is proud to play a vital role in the Australian Cancer Research Foundation (ACRF) Australian Centre of Excellence in Melanoma Imaging and Diagnosis (ACEMID).
Fifteen 3D total-body imaging systems will be rolled out across Queensland, New South Wales and Victoria with the aim of improving detection of early-stage melanoma and saving lives. MIA’s The Poche Centre will host one of the 3D systems.
It is estimated each 3D imaging machine will be able to provide 3,000 examinations each year, resulting in a total of approximately 100,000 digital ‘avatars’ within three years. This will create a world-wide data set of skin images which will inform clinical studies that will ultimately lead to changes in clinical decision making.
Funded by a highly competitive and prestigious $10 million grant from the ACRF, ACEMID is led by the University of Queensland, along with The University of Sydney and Monash University. It brings together three established NHMRC Centres of Research Excellence (CRE), including the CRE in Melanoma in which MIA leads, to combine cutting-edge imaging technology with a remote medicine network. Melanoma Institute Australia’s team members critical to the initiative include Professor Graham Mann, who is the NSW Chief Investigator (CI), and MIA Co-Medical Director Professor Richard Scolyer and Associate Professor Pascale Guitera who are experts in Diagnostic Intelligence. MIA’s Professor Andrew Spillane and Associate Professor Robyn Saw are Associate Investigators and Associate Professor Anne Cust and Associate Professor Rachael Morton feature in Clinical and Health Service Evaluation roles.
Co-Medical Director of MIA, Professor Richard Scolyer, said the initiative would provide enhanced access to specialist services for patients in rural and remote areas.
‘This infrastructure will provide the foundation for 3D total body imaging to be implemented within a remote medicine network, which is essential in a country as vast as Australia,’ Professor Scolyer said.
‘Three dimensional total body data will be transmitted from 3D imaging systems in geographically diverse locations to centralised image storage repositories, which will enable dermatologists and other skin specialists to review patient images. This will have immense impacts on patients by ensuring they are diagnosed quickly, early and accurately, regardless of where they live.’
The ACRF Australian Centre of Excellence in Melanoma Imaging and Diagnosis is a world first approach to tackling the burden of melanoma, and aims to achieve a “World Without Melanoma”. It will create a multi-disciplinary, multi-site team with the goal of improving the detection and diagnosis of melanoma whilst reducing variability in diagnosis and the incidence of thicker, poorer prognosis melanomas. The initiative also aims to reduce the financial burden of melanoma on the Australian public, decrease consultation times by taking a total-body image in milliseconds, and improve the health equity of rural and remote Australians in regards to melanoma diagnosis.
Congratulations to PhD Student, Tuba Nur Gide who was awarded a NSW National Council of Women Australia Day Award for her PhD research work.
Melanoma Institute Australia, is joining forces with the Wollongong Wolves Football Club in the battle to reduce Australia’s melanoma rates.
A new research project will evaluate the benefits and economic implications of CT and PET/CT imaging in patients with asymptomatic Stage III melanoma.
Sunscreen tips for a skin smart summer with the help of Professor Pascale Guitera, Dermatologist Associate for Melanoma Institute Australia.
Although survival rates for people with skin melanoma are increasing, these promises of hope are not being seen in uveal melanoma. Researchers are desperately trying to uncover new ways to treat this disease.
Lucinda Ryan and Carole Renouf talking about melanoma preventation and awareness on 720 ABC Perth.
Research projects led by MIA have been awarded almost $6 million in the latest NHMRC funding round which will enable vital progression of research into melanoma prevention and treatment.
The last decade has seen a surge in therapeutic options for advanced melanoma patients, thanks to research. However, not every patient responds to treatment and researchers are taking on the challenge to find out why.
Our first Global Melanoma Research Report shares selected research from around the world and here at MIA that is making a difference to the lives of melanoma patients now and in the future.
After 18 years as Director of the Sydney Melanoma Unit and then Executive Director of Melanoma Institute Australia, Professor John Thompson AO will step down from the position at the end of 2016.
Australian melanoma clinical practice guidelines have been published on a wiki platform for the first time as researchers try to keep up to date with emerging evidence.
Carole Renouf, CEO of Melanoma Institute Australia is asking young Australians who have been affected by melanoma to share their experiences with her.
Melanoma Institute Australia CEO Carole Renouf wants to make sure Aussies remember to take care of our skin as the festive season draws closer and we spend more time in the sun.
Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.